Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1642834 | 0.98 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL1627440 | 0.87 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL4149480 | 0.87 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL29541499 | 0.87 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL4143916 | 0.87 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL4140372 | 0.87 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL4148516 | 0.87 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL267542 | 0.87 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL4154180 | 0.87 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL3171617 | 0.87 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170934-A1 | MANUFACTURING PROCESS FOR NO-DONATING COMPOUNDS SUCH AS NO-DONATING DICLOFENAC | NICOX SA | 2009-07-02 | — | — | US | disclosed |
| US-20090096314-A1 | ELECTRIC MOTOR | HONDA MOTOR CO., LTD. (JP) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170934-A1 | MANUFACTURING PROCESS FOR NO-DONATING COMPOUNDS SUCH AS NO-DONATING DICLOFENAC | NOS2, NOS1, NOS3 | USP2 1318/4885TSHR 4651/4885KDM4E 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.